Skip to main content
Premium Trial:

Request an Annual Quote

New Products: BioTheranostics' BioT3 Cancer Test; Natera's Expanded Panorama


BioTheranostics has launched its BioT3 Metastatic Cancer Solution, a suite of genomics-based tests for metastatic cancer. The tests include CancerType ID for molecular classification of tumors; CancerTarget ID to identify actionable biomarkers associated with on-label targeted therapies; and CancerTreatment ID, which uses next-gen sequencing along with immunohistochemistry and fluorescent in situ hybridization to analyze around 50 cancer-related genes.

Natera has expanded its prenatal fetal aneuploidy test, Panorama, to include screening for five microdeletion syndromes. The expanded test will be available on March 1. DiGeorge syndrome, or 22q11.2 deletion syndrome, will be added as a standard option along with trisomies 21, 18, and 13; triploidy 13; and sex chromosome aneuploidies. Customers will also have the option to add screening for 1p36 deletion, Angelman, Cri-du-chat, and Prader-Willi syndromes.